Naegelin Y, et al. - By analyzing data from patients with secondary progressive multiple sclerosis (SPMS) at three multiple sclerosis centers located in Basel and Lugano, Switzerland, and Amsterdam, the Netherlands, between 2004 and 2017, researchers examined the progression of disability in rituximab-treated SPMS patients vs matched control patients never treated with rituximab. Participants in the study were diagnosed with SPMS, treated (57 eligible; 54 included) or not treated (504 eligible; 59 included) with rituximab and had at least 1 follow-up visit. According to this retrospective cohort study, patients with rituximab- treated SPMS had a significantly lower Expanded Disability Status Scale (EDSS) score for up to 10 years and a significantly delayed confirmed progression vs matched controls, implying that rituximab’s depletion of B-cells could help these patients therapeutically.